Johnson and Johnson’s Janssen subsidiary has inked a $509-million deal with Switzerland’s AC Immune that hands J&J exclusive rights to AC Immune’s ACI-35, an experimental anti-phosphrylated Tau Alzheimer’s vaccine.
The treatment works by stimulating a patient’s immune response to attack Tau proteins, which may cause the mind-destroying disease.
AC Immune said in a statement that the agreement includes one Alzheimer’s indication and an unspecified, non-Alzheimer’s indication.
